merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>lack of FDA oversight</answer>

<question_number>2</question_number>
<answer>direct competition</answer>

<question_number>3</question_number>
<answer>safety concerns</answer>

<question_number>4</question_number>
<answer>market share</answer>

<question_number>5</question_number>
<answer>legal basis</answer>

<question_number>6</question_number>
<answer>direct sales</answer>

<question_number>7</question_number>
<answer>appeal to Medicare patients</answer>

<question_number>8</question_number>
<answer>perceived safety</answer>

<question_number>9</question_number>
<answer>FDA shortage</answer>

<question_number>10</question_number>
<answer>lower pricing</answer>